SGM
AGMB

Seven Grand Managers’s AgomAb Therapeutics NV AGMB Stock Holding History

Seven Grand Managers’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618K Sell
47,600
-152,400
-76% -$1.72M 0.02% 169
2026
Q1 		$2.1M Buy
+200,000
New +$2.83M 0.14% 111

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Seven Grand Managers's AGMB Position: Q2 2026 in Review

Seven Grand Managers reduced its AgomAb Therapeutics NV (AGMB) stake by 76% in Q2 2026, selling an estimated $1.72M and leaving 47,600 shares worth $618K. The position accounts for 0.02% of the portfolio, ranked #169.

Seven Grand Managers first reported a position in AGMB in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.1M in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Seven Grand Managers held 47,600 shares of AgomAb Therapeutics NV worth $618K as of Q2 2026.
  • Seven Grand Managers sold 152,400 AgomAb Therapeutics NV shares in Q2 2026, an estimated $1.72M.
  • AgomAb Therapeutics NV made up 0.02% of Seven Grand Managers's portfolio in Q2 2026, its #169 holding.
  • Seven Grand Managers first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 2 quarters since.
  • Seven Grand Managers's AgomAb Therapeutics NV position peaked at $2.1M in Q1 2026.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.